Companies › Belite Bio
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Ophthalmology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tinlarebant (LBS-008) | – | Phase 3 | Geographic Atrophy; STGD1 | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05949593 | Tinlarebant (LBS-008) | Phase 3 | Geographic Atrophy | Ophthalmology | Jun 2027 |
| NCT06388083 | Tinlarebant (LBS-008) | Phase 2 | STGD1 | Ophthalmology | Feb 2028 |
Cash of $353m on 2025-12-31; operating cash outflow about $37m a year; runway about 114 months at that burn, to Jul 2035; 2 of 2 coming phase 2-3 readouts fall inside that runway
Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Cloudbreak Therapeutics Omikron Italia S.r.l. Viridian Therapeutics Aurion Biotech Smilebiotek Zhuhai
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.